Production & Manufacturing
BioPharma
Lack of Experience Hinders CDMOs In Cell And Gene Therapy
CDMOs (contract development and manufacturing organizations) are facing challenges due to the increasing number of companies preparing to scale up their cell and gene therapy manufacturing for Phase III trials and commercialization. While physical capacity has been blamed, the...
Drug Research
WHO & Republic of Korea Tie-Up For Biomanufacturing Training
The World Health Organisation as well as the Republic of South Korea have gone ahead and inked a MoU so as to establish a worldwide training hub when it comes to biomanufacturing. The worldwide training centre will go on...
BioPharma
Cell and Gene Therapy CDMO Targets North American Growth with Major US Acquisition
uBriGene, a cell & gene therapy contract development and manufacturing organization (CDMO), is expanding into the US market with the acquisition of a state-of-the-art GMP manufacturing facility from NASDAQ-listed company Mustang Bio, Inc.
The cell & gene therapy (CGT) CDMO...
News
UNDBIO to Build $100M Insulin Manufacturing Facility in West Virginia
UNDBIO, a South Korean pharmaceutical company focused on diabetic care, will spend $100 million to build an insulin manufacturing facility in West Virginia.
The project is expected to create 200 new jobs in the first three years, according to an April...
Press Releases
Lonza’s API Mid-Scale Manufacturing Facility Expansion in Nansha Enters Commercial Operation
Lonza announces the start of new mid-scale manufacturing assets at its API manufacturing center in Nansha, China. Commercial mid-scale operations are now underway at the expanded manufacturing facility, which was part of a CHF 20 million investment announced in...
News
How ‘First-Time Right’ Formulations Can Help Address the Challenge of Affordable Medicines
For years, global healthcare systems have been facing the triple threat of rising incidences of long-term conditions (LTC), aging populations and dwindling resources. At the same time, we have seen worldwide calls for affordable medicines – from the Jan...
News
By 2030, OSD Contract Manufacturing Will Be $54.7 Billion
The global oral solid dosage (OSD) contract manufacturing market is anticipated to reach $54.7 billion in value by 2030, exhibiting a compound annual growth rate (CAGR) of 6%, according to a market analysis.
As per data, oral solids are the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
